Kader AK - Search Results

1

Germline genetics in localized prostate cancer.

Ryan ST, Nguyen V, Bree KK, Holst DD, Kader AK. Ryan ST, et al. Among authors: kader ak. Curr Opin Urol. 2019 Jul;29(4):326-333. doi: 10.1097/MOU.0000000000000648. Curr Opin Urol. 2019. PMID: 31116139 Review.

2

Low Penetrance Germline Genetic Testing: Role for Risk Stratification in Prostate Cancer Screening and Examples From Clinical Practice.

Gaylis F, Bree KK, Dato P, Andriole GL, Kane CJ, Kader AK. Gaylis F, et al. Among authors: kader ak. Rev Urol. 2020;22(4):152-158. Rev Urol. 2020. PMID: 33927572 Free PMC article.

3

Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.

Sarkar RR, Parsons JK, Bryant AK, Ryan ST, Kader AK, McKay RR, D'Amico AV, Nguyen PL, Hulley BJ, Einck JP, Mundt AJ, Kane CJ, Murphy JD, Rose BS. Sarkar RR, et al. Among authors: kader ak. JAMA Intern Med. 2019 Jun 1;179(6):812-819. doi: 10.1001/jamainternmed.2019.0280. JAMA Intern Med. 2019. PMID: 31058923 Free PMC article.

4

Pathologic nodal downstaging in men with clinically involved lymph nodes undergoing radical prostatectomy: Implications for definitive locoregional therapy.

Ghali F, Daly WC, Hansen M, Hayn M, Sammon J, Beaule LT, Sarkar R, Murphy J, Kader AK, Derweesh I, Rose B, Ryan ST. Ghali F, et al. Among authors: kader ak. Urol Oncol. 2021 Feb;39(2):130.e1-130.e7. doi: 10.1016/j.urolonc.2020.08.035. Epub 2020 Oct 26. Urol Oncol. 2021. PMID: 33121914

5

Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.

Kader AK, Liss MA, Trottier G, Kim ST, Sun J, Zheng SL, Chadwick K, Lockwood G, Xu J, Fleshner NE. Kader AK, et al. Urology. 2015 Jan;85(1):165-70. doi: 10.1016/j.urology.2014.07.081. Urology. 2015. PMID: 25530379 Free PMC article.

6

Clarifying the Trade-Offs of Risk-Stratified Screening for Prostate Cancer: A Cost-Effectiveness Study.

Hendrix N, Gulati R, Jiao B, Kader AK, Ryan ST, Etzioni R. Hendrix N, et al. Among authors: kader ak. Am J Epidemiol. 2021 Oct 1;190(10):2064-2074. doi: 10.1093/aje/kwab155. Am J Epidemiol. 2021. PMID: 34023874 Free PMC article.

7

Impact of family history on prostate cancer mortality in white men undergoing prostate specific antigen based screening.

Liss MA, Chen H, Hemal S, Krane S, Kane CJ, Xu J, Kader AK. Liss MA, et al. Among authors: kader ak. J Urol. 2015 Jan;193(1):75-9. doi: 10.1016/j.juro.2014.07.085. Epub 2014 Jul 24. J Urol. 2015. PMID: 25066872

8

Reply: To PMID 25530379.

Kader AK, Liss MA, Xu J, Fleshner NE. Kader AK, et al. Urology. 2015 Jan;85(1):171. doi: 10.1016/j.urology.2014.07.083. Urology. 2015. PMID: 25530381 No abstract available.

9

The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data.

Crawford ED, Twardowski PW, Concepcion RS, Hafron JM, Harris RG, Moul JW, Gordan LN, Petrylak DP, Atkinson SN, Boldt-Houle DM, Keane TE, Higano CS, Henderson RJ, Kader AK, Hussain MH, Shore ND. Crawford ED, et al. Among authors: kader ak. J Urol. 2020 Apr;203(4):743-750. doi: 10.1097/JU.0000000000000577. Epub 2019 Oct 3. J Urol. 2020. PMID: 31580749

10

Prostate genetic score (PGS-33) is independently associated with risk of prostate cancer in the PLCO trial.

Liss MA, Xu J, Chen H, Kader AK. Liss MA, et al. Among authors: kader ak. Prostate. 2015 Sep;75(12):1322-8. doi: 10.1002/pros.23012. Epub 2015 May 15. Prostate. 2015. PMID: 25982801 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

78 results

Search Page

Filters